Su Ai-Xi, Ma Zi-Jie, Li Zong-Yin, Li Xue-Yan, Xia Lan, Ge Yi-Jun, Chen Gui-Hai
Department of Neurology (Sleep Disorder), The Affiliated Chaohu Hospital of Anhui Medical University, Chaohu, China.
Department of General Medicine, the First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Front Psychiatry. 2024 May 13;15:1360305. doi: 10.3389/fpsyt.2024.1360305. eCollection 2024.
To examine serum concentrations of neurotensin, pannexin-1 and sestrin-2, and their correlations with subjective and objective sleep quality and cognitive function in the patients with chronic insomnia disorder (CID).
Sixty-five CID patients were enrolled continuously and fifty-six good sleepers in the same period were served as healthy controls (HCs). Serum levels of neurotensin, pannexin-1 and sestrin-2 were measured by enzyme-linked immunosorbent assays. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and polysomnography, and mood was evaluated by 17-item Hamilton Depression Rating Scale. General cognitive function was assessed with the Chinese-Beijing Version of Montreal Cognitive Assessment and spatial memory was evaluated by Blue Velvet Arena Test (BVAT).
Relative to the HCs, the CID sufferers had higher levels of neurotensin (=5.210, <0.001) and pannexin-1 (=-4.169, <0.001), and lower level of sestrin-2 (=-2.438, =0.015). In terms of objective sleep measures, pannexin-1 was positively associated with total sleep time (=0.562, =0.002) and sleep efficiency (=0.588, =0.001), and negatively with wake time after sleep onset (=-0.590, =0.001) and wake time (=-0.590, =0.001); sestrin-2 was positively associated with percentage of rapid eye movement sleep (=0.442, =0.016) and negatively with non-rapid eye movement sleep stage 2 in the percentage (=-0.394, =0.034). Adjusted for sex, age and HAMD, pannexin-1 was still associated with the above objective sleep measures, but sestrin-2 was only negatively with wake time (=-0.446, =0.022). However, these biomarkers showed no significant correlations with subjective sleep quality (PSQI score). Serum concentrations of neurotensin and pannexin-1 were positively associated with the mean erroneous distance in the BVAT. Adjusted for sex, age and depression, neurotensin was negatively associated with MoCA score (=-0.257, =0.044), pannexin-1 was positively associated with the mean erroneous distance in the BVAT (=0.270, =0.033).
The CID patients had increased neurotensin and pannexin-1 and decreased sestrin-2 in the serum levels, indicating neuron dysfunction, which could be related to poor sleep quality and cognitive dysfunction measured objectively.
检测慢性失眠障碍（CID）患者血清中神经降压素、泛连接蛋白-1和 sestrin-2的浓度，并探讨它们与主观和客观睡眠质量及认知功能的相关性。
连续纳入65例CID患者，并选取同期56名睡眠良好者作为健康对照（HCs）。采用酶联免疫吸附测定法检测血清中神经降压素、泛连接蛋白-1和 sestrin-2的水平。使用匹兹堡睡眠质量指数（PSQI）和多导睡眠图评估睡眠质量，采用17项汉密尔顿抑郁量表评估情绪。使用中文版蒙特利尔认知评估量表评估总体认知功能，通过蓝丝绒竞技场测试（BVAT）评估空间记忆。
与HCs相比，CID患者的神经降压素水平更高（=5.210，<0.001），泛连接蛋白-1水平更高（=-4.169，<0.001），而sestrin-2水平更低（=-2.438，=0.015）。在客观睡眠指标方面，泛连接蛋白-1与总睡眠时间呈正相关（=0.562，=0.002）和睡眠效率呈正相关（=0.588，=0.001），与睡眠开始后的觉醒时间呈负相关（=-0.590，=0.001）和觉醒时间呈负相关（=-0.590，=0.001）；sestrin-2与快速眼动睡眠百分比呈正相关（=0.442，=0.016），与非快速眼动睡眠2期百分比呈负相关（=-0.394，=0.034）。在调整性别、年龄和汉密尔顿抑郁量表（HAMD）评分后，泛连接蛋白-1仍与上述客观睡眠指标相关，但sestrin-2仅与觉醒时间呈负相关（=-0.446，=0.022）。然而，这些生物标志物与主观睡眠质量（PSQI评分）无显著相关性。血清神经降压素和泛连接蛋白-1浓度与BVAT中的平均错误距离呈正相关。在调整性别、年龄和抑郁因素后，神经降压素与蒙特利尔认知评估量表（MoCA）评分呈负相关（=-0.257，=0.044），泛连接蛋白-1与BVAT中的平均错误距离呈正相关（=
